Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
Last trade$22.04
Day change-$0.455 (-2.02%)
Day range$21.98 – $22.98
Volume202,015
Market cap$1.39B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.39B
Price / earnings
—
Price / book
2.81×
Price / sales
—
EV / sales
—
EV / EBITDA
-3.43×
Profitability
Earnings per share
-$1.07
Return on assets
-12.48%
Return on equity
-13.4%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
14.8×
Quick ratio
14.8×
Cash ratio
9.74×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$59.13M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for DMRA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Revenue
$0
$0
$0
Cost of revenue
$0
$0
$0
Gross profit
$0
$0
$0
Selling, general and administrative
$11.39M
$9.45M
$7.03M
Research and development
$25.48M
$25.54M
$23.78M
Total operating expenses
$36.86M
$34.99M
$30.81M
Operating income
-$36.86M
-$34.99M
-$30.81M
Interest expense
$0
$0
$0
Income before taxes
-$31.99M
-$30.92M
-$27.74M
Income taxes
$0
$255K
$42K
Net income
-$31.99M
-$31.17M
-$27.78M
Net income attributable to common shareholders
-$24.75M
-$24.06M
-$21.33M
EBITDA
-$36.86M
-$34.99M
-$30.81M
Basic earnings per share
-$0.40
-$0.39
-$0.62
Diluted earnings per share
-$0.40
-$0.39
-$0.62
Recent news
Company coverage with links to the original publishers.
Damora Therapeutics granted equity awards to five newly-hired non-executive employees on October 1, 2026, consisting of options to purchase 144,400 ordinary shares at $21.28 per share with a 10-year term. The inducement grants were approved by the Compensation Committee as material incentives for employment acceptance.
Damora Therapeutics announced equity inducement grants to three newly-hired non-executive employees on September 1, 2026. The grants consist of options to purchase 135,400 ordinary shares at $28.18 per share with a 10-year term and standard 4-year vesting schedule. The awards were approved by the Compensation Committee as material inducements for employment.
Damora Therapeutics announced the appointment of Jennifer Jarrett as President and Chief Executive Officer, granting her 500,000 RSUs and options to purchase 1.5 million shares. The company also granted equity awards to four non-executive employees as inducement for joining the biotechnology firm focused on treating blood disorders.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.